maple syrup

General Material Information

Preferred name	maple syrup
Trivial Name	Maple syrup
CAS Number	8029-81-0
ECHA Number	232-441-1
FDA UNII	Search
FDA Mainterm	Maple syrup
Synonyms	maple-sap syrup Maple-sap products, syrups Maple sap products, maple syrup Syrups (sweetening agents), maple Maple sirup Syrups maple-sap products Maple-sap products, syrup Syrup maple-sap products Maple-sap products, maple syrup Maple syrups

US / EU / FDA / JECFA / FEMA / Scholar / Patents

Google Scholar	Start search
Google Books	Start search
Google Patents	Start search
Perfumer & Flavorists	Start search
EU Patents	Start search
PubMeb	Start search
NCBI	Start search

Literature & References

Pubchem (sid):

135332398

Publications by PubMed
Chemical compositional, biological, and safety studies of a novel maple syrup derived extract for nutraceutical applications.
Nonnutritive sweeteners are not supernormal stimuli.
Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach.
Preservation of high phenylalanine ammonia lyase activities in roots of Japanese Striped corn: a potential oral therapeutic to treat phenylketonuria.
Maple Syrup Urine Disease Complicated with Kyphoscoliosis and Myelopathy.
[The use of low-calorie sweeteners].
Adipose transplant for inborn errors of branched chain amino acid metabolism in mice.
Drosophila miR-277 controls branched-chain amino acid catabolism and affects lifespan.
Potential of fluorescence spectroscopy for the characterisation of maple syrup flavours.
Treatment of acute decompensation of maple syrup urine disease in adult patients with a new parenteral amino-acid mixture.
Maple polyphenols, ginnalins A-C, induce S- and G2/M-cell cycle arrest in colon and breast cancer cells mediated by decreasing cyclins A and D1 levels.
Risk assessment and risk management at the Canadian Food Inspection Agency (CFIA): a perspective on the monitoring of foods for chemical residues.
Maple sap predominant microbial contaminants are correlated with the physicochemical and sensorial properties of maple syrup.
Analysis of human male armpit sweat after fenugreek ingestion: Characterisation of odour active compounds by gas chromatography coupled to mass spectrometry and olfactometry.
Further investigation into maple syrup yields 3 new lignans, a new phenylpropanoid, and 26 other phytochemicals.
Comparison of nonfried apple snacks with commercially available fried snacks.
Maple syrup phytochemicals include lignans, coumarins, a stilbene, and other previously unreported antioxidant phenolic compounds.
Antioxidant activity, inhibition of nitric oxide overproduction, and in vitro antiproliferative effect of maple sap and syrup from Acer saccharum.
Changing carbon isotope ratio of atmospheric carbon dioxide: implications for food authentication.
Classical maple syrup urine disease and brain development: principles of management and formula design.
Maple syrup-production, composition, chemistry, and sensory characteristics.
Total antioxidant content of alternatives to refined sugar.
Improved detection of sugar addition to maple syrup using malic acid as internal standard and in 13C isotope ratio mass spectrometry (IRMS).
The generation of formaldehyde in cigarettes--Overview and recent experiments.
A new protein substitute for adolescents and adults with maple syrup urine disease (MSUD).
Branched-chain amino acids and brain function.
Legal strategies to address the misrepresentation of Vermont maple syrup.
Microwave processing of maple sap to maple syrup and maple syrup products.
Spectrofluorimetric determination of formaldehyde in maple syrup.
Utility of hemodialysis in maple syrup urine disease.
Detection of added beet or cane sugar in maple syrup by the site-specific deuterium nuclear magnetic resonance (SNIF-NMR) method: collaborative study.
Whole-body L-leucine oxidation in patients with variant form of maple syrup urine disease.
Limitations in the use of ozone to disinfect maple sap.
Diagnosis of inborn errors of metabolism.
4,5-dimethyl-3-hydroxy-2[5H]-furanone (sotolone)--the odour of maple syrup urine disease.
Peculiar odor of traditional food and maple syrup urine disease.
Sugar nucleotide concentrations in red blood cells of patients on protein- and lactose-limited diets: effect of galactose supplementation.
Making maple syrup: hazardous a vocational ingestion of raw sap in a patient with nut and tree pollen sensitivity.
[Lists of food exchanges for use in phenylketonuria and maple-syrup urine disease].
[Methodology of care for children with phenylketonuria and maple-syrup urine disease].
Acrodermatitis enteropathica-like syndrome secondary to isoleucine deficiency during treatment of maple syrup urine disease.
Nutrient intakes of adolescents with phenylketonuria and infants and children with maple syrup urine disease on semisynthetic diets.
Sample preparation bias in carbon stable isotope ratio analysis of fruit juices and sweeteners.
Inherited enzyme deficiencies in livestock.
Dietary management of inborn errors of amino acid metabolism with protein-modified diets.
High levels of dietary amino and branched-chain alpha-keto acids alter plasma and brain amino acid concentrations in rats.
Selenium in pediatric nutrition.
Analysis of selenium content in commercial dietetic products.
Evaluation of branched-chain amino acid intake in children with maple syrup urine disease and methylmalonic aciduria.
Gas chromatographic determination of formaldehyde in maple syrup as 2,4-dinitrophenylhydrazone derivative.
[Isolated isoleucine deficiency in diet therapy of a case of maple syrup urine disease].
Azetidine-2-carboxylic acid contaminated dietary proline as a cause of urinary excretion of 4-amino-2-(S-cysteinyl)butyric acid in patients on oral treatment with a synthetic diet.
Prospective study of maple-syrup-urine disease for the first four days of life.
Acidosis associated with dietotherapy of maple syrup urine disease.
Dietary management of maple-sirup-urine disease: extension of equivalency systems.
Dietary restriction in inborn errors of amino acid metabolism.
Selenium concentration and glutathione peroxidase activity in blood of New Zealand infants and children.
Maple syrup urine disease: emergency treatment of the neonate.
Management of maple syrup urine disease in Canada. Committee for improvement of Hereditary Disease Management.
Dietary treatment of maple sirup urine disease (branched-chain ketoaciduria).
The dietary therapy of inherited metabolic disease.
Mineral and trace-metal balances in children receiving normal and synthetic diets.
Leucine equivalency system in managing branched chain ketoaciduria.
Folic acid deficiency secondary to a diet for maple syrup urine disease.

Other Information

FDA Listing of Food Additive Status:

View

Suppliers

Astral Extracts	Bascom Family Farms
Horner International

PhysChem Properties

Material listed in food chemical codex	No
Solubility
water	Yes

Organoleptic Properties

Flavor Type: Caramellic
maple, caramellic
General comment	Maple syrup

Safety Information

Safety information


Hazards identification

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements

Pictogram

Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
Not determined
Dermal Toxicity:
Not determined
Inhalation Toxicity:
Not determined

Safety in use information

Category:
flavoring agents, food additives
Recommendation for maple syrup usage levels up to:
	not for fragrance use.

Safety references

EPA ACToR:Toxicology Data

EPA Substance Registry Services (SRS):Registry

National Institute of Allergy and Infectious Diseases:Data

Chemidplus:0008029810